pCR8-CDK12
(Plasmid
#208347)
-
PurposeGateway cloning entry vector with CDK12. Must be recombined into a DEST vector for expression.
-
Depositing Lab
-
Publication
-
Sequence Information
Ordering
| Item | Catalog # | Description | Quantity | Price (USD) | |
|---|---|---|---|---|---|
| Plasmid | 208347 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $89 | |
Backbone
-
Vector backbonepCR8
-
Backbone manufacturerInvitrogen (K250020)
- Backbone size w/o insert (bp) 2790
- Total vector size (bp) 7306
-
Modifications to backboneCDK12 was PCR amplified and TOPO-TA cloned into pCR8/GW/TOPO
-
Vector typeGateway: ENTRY vector
Growth in Bacteria
-
Bacterial Resistance(s)Spectinomycin, 50 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)NEB Stable
-
Copy numberUnknown
Gene/Insert
-
Gene/Insert namecyclin dependent kinase 12
-
SpeciesH. sapiens (human)
-
Insert Size (bp)4473
-
Entrez GeneCDK12 (a.k.a. CRK7, CRKR, CRKRS)
Resource Information
-
Supplemental Documents
-
A portion of this plasmid was derived from a plasmid made byCDK12 was PCR cloned from a plasmid purchased from Vector Builder (VB180725-1308KYV)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pCR8-CDK12 was a gift from Peter S Nelson (Addgene plasmid # 208347 ; http://n2t.net/addgene:208347 ; RRID:Addgene_208347) -
For your References section:
Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies. Frank S, Persse T, Coleman I, Bankhead III A, Li D, De-Sarkar N, Wilson D, Rudoy D, Vashisth M, Galipeau P, Yang M, Hanratty B, Dumpit R, Morrissey C, Corey E, Montgomery RB, Haffner MC, Pritchard CC, Vasioukhin V, Ha G, Nelson PS. eLife 2025 10.7554/eLife.100081.2